There are 2789 resources available
1075P - Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma
Presenter: Caroline Robert
Session: ePoster Display
1076P - Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group study
Presenter: Mehmet Alpaslan Ozgun
Session: ePoster Display
1077P - Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy: A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE)
Presenter: Georgina Long
Session: ePoster Display
1078P - Real-world data on patients with melanoma brain metastases and outcome related to locoregional treatment modalities and systemic therapy
Presenter: Sidsel Pedersen
Session: ePoster Display
1080P - HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program
Presenter: Jean Jacques Grob
Session: ePoster Display
1081P - Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
Presenter: Jesper Breeschoten
Session: ePoster Display
1082P - Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
Presenter: Filip Janku
Session: ePoster Display
1083P - A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
Presenter: Alexander Shoushtari
Session: ePoster Display
1084P - PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Presenter: Caroline Robert
Session: ePoster Display